Drug intelligence / Profile preview

Viaskin PT

Development stage
Phase 1
Lead developer
DBV Technologies
Modality
Vaccines & Immunotherapeutics
Administration
Epicutaneous, Transdermal, Topical
01

Overview

Viaskin PT is an investigational epicutaneous immunotherapy (EPIT) patch developed by DBV Technologies for the delivery of pertussis toxin antigen through intact skin. The technology is based on the proprietary Viaskin platform, which enables non-invasive administration of biologically active compounds to the immune system via the skin. The primary mechanism involves presenting pertussis toxin to immune cells in a controlled manner, aiming to induce a protective immune response without systemic exposure or injection. This approach is being explored as a booster vaccine strategy for whooping cough (pertussis), with early-stage clinical trials assessing safety and immunogenicity[8]. DBV Technologies has previously advanced similar EPIT patches for food allergies such as peanut and milk.

Brand names
Viaskin PT
Other names
Viaskin-PTViaskin Pertussis Toxin patch

Beyond the preview

Go deeper on Viaskin PT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viaskin PT.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call